It’s hard to believe that we’re already at the end of the first quarter. It feels like just yesterday that we pulled ourselves back into the office after the December holidays ready to take on the challenges of a new year.
For us at Advera Health Analytics the last three months have been a blur – a caffeine and sugar-induced blur. I’ve spent the last couple of days putting together a first quarter review for our shareholders and it’s remarkable to look back and see how much we’ve achieved in such a short period of time.
Certainly the biggest moment over the past three months was launching Evidex, our new data platform that combines clinical trial evidence data with post-marketed FAERS data and analysis. Evidex has been on our roadmap for well over a year and marks a significant turning point in the scope of our coverage areas and the scale of the data and analytics that we provide to our clients. It’s still early days, but the response has been overwhelming. Their only real concern – when are you going to have more coverage?? It’s coming soon, stay tuned.
No less monumental was the publication of our RxSignal methods and results paper in the peer reviewed journal Drug Safety. The study, headed by our own Dr. Keith Hoffman with support of Dr. Nicholas Tattonetti from Columbia University and our amazing analyst and tech teams details how we accurately predict future FDA warnings, alerts, and label changes by examining FAERS data. RxSignal is one of the cornerstone analytic tools of our Evidex platform and something that our clients have come to rely on to make formulary, prescription, and market positioning decisions. It was a great accomplishment to have our worked once again pass through the peer review and publication process at a prominent academic and industry journal.
Drug Evidence Reviews
Since we launched Advera Health, our analyst team has published reviews and insights from the data we curate under the name Drug Safety Monitor. With the launch of Evidex and our expanded scope of coverage, those Drug Safety Monitors morphed into the more comprehensive Drug Evidence Reviews. The Drug Evidence Reviews focus attention on the clinical evidence we’ve accumulated on key new drugs and compare those new drugs to the safety profiles we’ve created for currently marketed drugs. In this first quarter we’ve published Drug Evidence Reviews on Zepatier (elbasvir, grazoprevir), Nucala (mepolizumab), and Marizev (omarigliptin). You can click the links in the names to request a copy of any of these reports.
Those reports generated a lot of media interest including coverage in MedPage Today, FiercePharma, and AJMC. Here's a snapshot of the type of comparative analyses our team has been generating for these reviews, with the full tables available through this free report download:
It’s been a great start to the year for us at Advera Health. And we’re not slowing down – look for increased indication coverage on Evidex starting in the second quarter and a whole lot of other new and exciting developments.
Brian M. Overstreet, President, Advera Health Analytics, Inc.